4/A: Lucid Diagnostics Director Amends Filing to Correct Beneficial Ownership, Revealing Increased Stake

Lucid Diagnostics Inc. Director Dennis Matheis filed an amended Form 4, correcting his reported beneficial ownership to reflect a significantly larger stake in the company following recent stock acquisitions.

Summary

• Dennis Matheis, a Director of Lucid Diagnostics Inc. (LUCD), filed a Form 4/A amendment to correct previously reported beneficial ownership of common stock.
• The amendment clarifies that the initial Form 4 filing on May 22, 2025, omitted 215,443 shares held by Mr. Matheis prior to the reported transactions, which included 52,718 shares distributed from a limited partnership where he is a partner.
• Between May 20 and May 22, 2025, Mr. Matheis acquired a total of 340,000 shares of Lucid Diagnostics common stock through open market purchases.
• Specifically, he acquired 187,098 shares on May 20, 2025, at a weighted average price of $1.295 per share (ranging from $1.265 to $1.30).
• On May 21, 2025, he acquired 129,684 shares at a weighted average price of $1.3226 per share (ranging from $1.315 to $1.32).
• On May 22, 2025, he acquired an additional 33,218 shares at a weighted average price of $1.3184 per share (ranging from $1.305 to $1.32).
• Following these transactions and the correction, Mr. Matheis's total direct beneficial ownership of Lucid Diagnostics common stock is 565,443 shares.

Sentiment

Score: 7

Explanation: The sentiment is positive due to significant insider buying by a director, indicating confidence in the company. The amendment itself is a technical correction, improving transparency.

Positives

• A director increasing their stake in the company through open market purchases often signals confidence in the company's future prospects and valuation.
• The correction in the filing provides greater transparency and accuracy regarding the director's total beneficial ownership.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance.

Management Comments

• The filing indicates that the amendment was made 'solely to correct the number of shares beneficially owned by the reporting person following the reported transactions. The initial filing omitted from this amount 215,443 shares (which includes the 52,718 shares referenced in footnote 4) held by the reporting person prior to the reported transactions.'

Industry Context

Insider buying, such as that reported by a director, is generally viewed by the market as a positive signal, indicating management's belief in the company's intrinsic value or future prospects. This activity is common across industries and is closely monitored by investors for insights into management's confidence.

Related Party Transactions

• The reported beneficial ownership includes 52,718 shares of Lucid common stock distributed on a pro rata basis to the reporting person by a limited partnership of which the reporting person is a limited partner.

Stakeholder Impact

• Shareholders may view the director's increased stake as a positive indicator of management's alignment with shareholder interests and confidence in the company's future.
• The correction ensures more accurate public disclosure, benefiting all stakeholders who rely on SEC filings for investment decisions.

Key Dates

Keywords

Lucid Diagnostics, LUCD, insider trading, Form 4/A, beneficial ownership, director stock acquisition, common stock, SEC filing, corporate governance